ORIGINAL ARTICLES
Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics

https://doi.org/10.1016/S1081-1206(10)62432-5Get rights and content

Background

Leukotrienes (LTs) have been implicated as major mediators of aspirin-(ASA)-induced respiratory reactions. It was therefore logical to assume that an inhibitor of 5-lipoxygenase (5-LO), such as zileuton, given before and during oral challenges with ASA, might prevent ASA-induced respiratory reactions. Indeed, in prior studies, pretreatment of ASA-sensitive respiratory disease patients with leukotriene modifiers eliminated or attenuated respiratory reactions upon re-challenge with the previously established provoking dose of ASA. However, doses higher than the provoking doses were not administered during these reported studies.

Objective

We wished to determine whether zileuton pretreatment could prevent ASA-induced respiratory reactions in our six volunteers with aspirin-sensitive respiratory disease when ASA challenge doses were started below the usual provoking dose of 60 mg and then increased until a respiratory reaction occurred.

Method

Aspirin sensitivity was established previously in all six patients during a prior ASA oral challenge. In this study, pretreatment with zileuton 600 mg qid was initiated 7 days prior to, and continued during oral ASA challenges. Patients underwent single-blind oral ASA challenges with escalating doses of ASA, every 3 hours, according to our standard protocol.

Results

All six patients reacted to doses of ASA between 45 and 325 mg. Four patients experienced bronchospasm (FEV1 declined 19% to 53%) while receiving zileuton. All six had naso-ocular reactions. Concentrations of urine LTE4 also increased significantly (mean 334 pg/mg Cr at baseline, increasing to 1024 pg/mg Cr at respiratory reactions).

Conclusions

During ASA challenges, zileuton, in standard doses of 600 mg qid was associated with increased synthesis of LTs in five of six patients and nasoocular reactions in all six patients, as well as bronchospasm in four patients.

REFERENCES (24)

  • RJ Horwitz et al.

    The role of leukotriene modifiers in the treatment of asthma

    Am J Respir Crit Care Med

    (1998)
  • PM O'Byrne et al.

    Antileukotrienes in the treatment of asthma

    Ann Intern Med

    (1997)
  • Cited by (45)

    • The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology

      2021, Journal of Allergy and Clinical Immunology
      Citation Excerpt :

      Few trials have attempted to determine differences of an LTRA as compared with a 5-LO inhibitor in the attenuation of lower airway symptoms. In an observational study, an LTRA was found to be superior to a 5-LO inhibitor (zileuton),88 and another small study of 6 subjects found that zileuton had minimal effects in 4 of 6 subjects.89 There is also limited data on the effects of combining a 5-LO inhibitor with an LTRA before desensitization.

    • Lipid Mediators in Aspirin-Exacerbated Respiratory Disease

      2016, Immunology and Allergy Clinics of North America
      Citation Excerpt :

      Although zileuton was promising given its ability to reduce the production of CysLTs as well as LTB4, its clinical utility has been variable, likely because of its failure to completely block LT formation. Other studies have shown that although zileuton can increase the threshold dose of aspirin required to provoke a reaction, the effect of 5-LO inhibition can be overcome.67 The widespread use of zileuton has been complicated by hepatotoxicity and the need for frequent dosing.

    • Performing Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease

      2016, Immunology and Allergy Clinics of North America
      Citation Excerpt :

      Leukotriene receptor blockers montelukast and zafirlukast have been shown to not completely mask the upper respiratory symptoms during oral NSAID challenge3,6; they are, thus, the preferred LTMDs to use. Zileuton, a 5-lipoxygenase inhibitor, has not been studied as rigorously in this context; but one small study showed that it did not mask symptoms completely in 6 out of 6 patients.7 The potential disadvantage of using zileuton as pretreatment is a false-negative result.

    • Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease

      2015, Journal of Allergy and Clinical Immunology: In Practice
      Citation Excerpt :

      Double-blinded, placebo-controlled trials showed that zileuton improved pulmonary function, diminished nasal dysfunction, and inhibited aspirin-induced bronchoconstriction.18,19 The finding that zileuton provides both upper and lower respiratory tract effects is promising.20,21 Although we are unable to generalize worldwide, in our practice, cost and insurance coverage is a major limiting factor in the accessibility to zileuton.

    • Allergy diagnostic testing: An updated practice parameter

      2008, Annals of Allergy, Asthma and Immunology
    View all citing articles on Scopus

    Intramural Grant (#97-20) from Academic Affairs, Scripps Clinic and GCRC of Scripps Clinic, Scripps Green Hospital, The Scripps Research Institute (Grant #M01RR00833).

    View full text